BRCA1-induced ovarian oncogenesis

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 89-97

  Dubeau, Louis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; ESTRADIOL; ESTROGEN; MUELLERIAN INHIBITING FACTOR; PROGESTERONE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CARCINOMA; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DNA REPAIR; ESTRUS CYCLE; FEMALE; GENE INACTIVATION; GENE ISOLATION; GENETIC PREDISPOSITION; GRANULOSA CELL; HETEROZYGOTE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UTERINE TUBE CARCINOMA;

EID: 84934438835     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_8     Document Type: Review

References (38)

1. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
2. Knudsen AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
3. Deng C-X. BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucl Acids Res 2006;34:1416-26.
4. Deng CX, Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 2000;19:1059-64.
5. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000;408:429-32.
6. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
7. Zheng L, Li S, Boyer TG, Lee WH. Lessons learned from BRCA1 and BRCA2. Oncogene 2000;19:6159-75.
8. Cornelis RS, Neuhausen SL, Johansson O, et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995;13:203-10.
9. Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1- linked kindreds. Cancer Res 1994;54:6069-72.
10. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 1992;2:128-31.
11. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. BRCA1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996;12:191-4.
12. Shen SX, Waeaver Z, Xu XL, et al. A targeted disruption of the murine BRCA1 gene causes y-radiation hypersensitivity and genetic instability. Oncogene 1998;17:3117-24.
13. Rice J, Massey-Brown K, Futscher B. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998;1998(17):1807-12.
14. Tomlinson GE, Chen TT-L, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998;58:3237-42.
15. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2/M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform deficient cells. Mol Cell 1999;3:389-95.
16. Ouchi M, Fujiuchi N, Sasai K, et al. BRCA1 phosphorylation by aurora in the regulation of G2 to M transition. J Biol Chem 2004;279:19643-8.
17. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group [see comments]. Am J Epidemiol 1992;136(10):1184-203.
18. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis 1987;40(Suppl 2):59S-69S.
19. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: A population-based case-control study. Fertil Steril 2004;82:186-95.
20. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. New Engl J Med 1998;339:424-8.
21. Josso N, di Clemente N, Gouedart L. Anti-mullerian hormone and its receptors. Molec Cell Endocrinol 2001;179:25-32.
22. de Vet A, Laven JSE, de Jong FH, Themmen APN, Fauser BCJM. Antimullerian hormone serum levels: A putative marker for ovarian aging. Fertil Steril 2002;77:357-62.
23. Gustafson ML, Lee MM, Scully RE, et al. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. New Engl J Med 1992;326:466-71.
24. Long W-Q, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000;85:540-4.
25. Durlinger AMJG, Gruijters MJG, Kramer P, Karels B, Grootegoed JA, Themmen PN. Antimullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002;143:1076-84.
26. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol Oncol 1999;72:437-42.
27. Masiakos PT, MacLaughlin DT, Maheswaran S, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99.
28. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 2002;8:2640-6.
29. Dutertre M, Gouedart L, Xavier F, et al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-mullerian hormone in transgenic mice. Endocrinology 2001;142:4040-6.
30. Conolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389-97.
31. Chodankar R, Kwang S, Sangiorgi F, et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005;15:561-5.
32. Griswold MD, Heckert L, Linder C. The molecular biology of the FSH receptor. J Steroid Biochem Mol Biol 1995;53:215-8.
33. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-9.
34. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87:52-6.
35. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
36. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nature Med 1996;2:1179-83.
37. Hu Y, Ghosh S, Amleh A, et al. Modulation of aromatase expression by BRCA1: A possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343-8.
38. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005;23:8629-35.